Back to search results

Isturisa Treatment for Mild Autonomous Cortisol Secretion (MACS)

This study is looking at how a medication called Isturisa (osilodrostat) affects people with Mild Autonomous Cortisol Secretion (MACS). MACS is a condition where your adrenal glands make too much cortisol, even without the severe symptoms of Cushing syndrome. Researchers want to see if Isturisa can improve health issues often linked to MACS, such as changes in blood sugar, body weight, and bone strength. They will also look at how it impacts your quality of life. You might be able to join if you are an adult aged 18 or older, have a MACS diagnosis confirmed by imaging and a specific cortisol level after a 1 mg dexamethasone suppression test (DST). The study aims to enroll 10 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. The study plans to enroll 10 participants.
What's involved
You would have blood tests and body measurements (like weight and bone density scans) at the start, and then every 3 months for up to 2 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 2 years, with some measurements taken at 1 year and 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07247058

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Recruiting
PHASE4Ages 18+InterventionalTreatment
Johns Hopkins University
~10 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:Osilodrostat (Isturisa)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in fasting glucose, HbA1c
Measured over Baseline, and then every 3 months up to 2 years
+4 more outcomes measured

Conditions

Mild Autonomous Cortisol Secretion (MACS)

Explore related trials

Adrenal Cortical AdenomaMild Autonomous Cortisol Secretion

NCT07247058

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Johns Hopkins University School of Medicine

    Baltimore, Marylandstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Amir Hamrahian, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Pooneh Jabbaripour Sarmadian, MD
[email protected]
667-208-8367
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged ≥18 years.
Diagnosis of mild autonomous cortisol secretion (MACS) defined by:
Serum cortisol \>1.8 µg/dL after 1 mg overnight dexamethasone suppression test (DST).
Presence of adrenal adenoma confirmed by imaging (CT or MRI).
Ability to provide informed consent.
Willingness to undergo study procedures including DEXA scan and laboratory assessments.

Exclusion

Known diagnosis of Cushing's syndrome or overt hypercortisolism.
Current or recent (within 3 months) treatment with glucocorticoids or medications affecting cortisol production (e.g., ketoconazole, metyrapone).
Severe hepatic impairment or renal failure.
Pregnancy or breastfeeding.
Known allergy or contraindication to osilodrostat (Isturisa).
Participation in another interventional clinical trial within the last 30 days.
Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or safety.

What this trial measures

  • Change in fasting glucose, HbA1cBaseline, and then every 3 months up to 2 years

    glycemic control: fasting glucose, HbA1c

  • Change in bone mineral density (g/cm²)Baseline, 1 year, and 2 years

    Bone mineral density (g/cm²) measured by DEXA scan.

  • Change in body weight (kg) from baseline during Isturisa treatmentBaseline and every 3 months up to 2 years

    Change in body weight will be measured at baseline and every follow-up visit (approximately every 3 months) throughout the 2-year treatment period with Isturisa.

  • Change in lipid profile from baseline during Isturisa treatmentBaseline and every 3 months up to 2 years

    Serum lipid profile (LDL-C, HDL-C, total cholesterol, triglycerides) will be assessed at baseline and every follow-up visit (approximately every 3 months) during the 2-year treatment period.

  • Change in body composition (kg)baseline, 1 year and 2 years

    Body composition including lean mass and fat mass (kg) measured by DEXA scan.